Blood cells and vascular cell interactions in diabetes

Area of Science:

• Endocrinology
• Vascular Biology
• Immunology

Background:

• Diabetic vasculopathy, characterized by arteriopathy, coronary ischemia, and renal failure, is a major complication of diabetes.
• Advanced glycation end products (AGE) are implicated in vascular dysfunction, binding to the receptor for advanced glycation end products (RAGE) on endothelial cells.
• AGE-RAGE interaction triggers oxidative stress, impairs vascular barrier function, increases permeability, and upregulates VCAM-1 expression, promoting monocyte adhesion and emigration.

Purpose of the Study:

• To investigate the role of AGE-RAGE axis in diabetic vascular complications.
• To evaluate the therapeutic potential of recombinant RAGE in preventing diabetic atherosclerosis.

Main Methods:

• Studies were conducted in diabetic animals and ApoE null diabetic mice models of atherosclerosis.
• Recombinant RAGE, produced in insect cells, was administered to these animals.
• Vascular permeability, VCAM-1 expression, and atherosclerotic lesion development were assessed.

Main Results:

• Recombinant RAGE administration effectively corrected vascular hyperpermeability in diabetic models.
• The treatment prevented the development of atherosclerosis in diabetic ApoE null mice.
• AGE-RAGE axis activation contributes to early vascular alterations in diabetes.

Conclusions:

• The AGE-RAGE pathway is a key mediator of diabetic vascular complications, including atherosclerosis.
• Targeting RAGE with recombinant RAGE offers a potential therapeutic strategy to mitigate diabetic vasculopathy and its sequelae.